LIST OF FIGURES

Sr. No.	Titles	Page No.
Chapter 2: Literature Review		
Fig. 2.1	Pathogenesis of psoriasis	16
Fig. 2.2	Types of psoriasis	18
Fig. 2.3	Clinical symptoms of Atopic dermatitis	19
Fig. 2.4	Pathophysiology of Atopic Dermatitis	20
Fig. 2.5	Conventional topical treatments available for Atopic dermatitis	21
Fig. 2.6	Different mechanism of actions of Antimicrobial Peptides	23
Fig. 2.7	Structure of Omiganan	24
Fig. 2.8	Various vital factors which affect the percutaneous absorption of drugs	28
Fig. 2.9	Several permeation enhancement techniques employed for drug delivery	29
Fig. 2.10	Conventional drug delivery systems used for topical delivery	30
Fig. 2.11	Nano-carriers based drug delivery systems for dermal route	31
Chapter 3: Analytical Method		
Fig. 3.1	Typical HPLC chromatogram of Omiganan (3 µg/ml)	57
Fig. 3.2	Overlay plot of Omiganan by HPLC method	58
Fig. 3.3	Calibration plot of Omiganan by HPLC method	58
Fig. 3.4	Typical HPLC chromatogram of DPK-060 (1 µg/ml)	61
Fig. 3.5	Overlay plot of DPK-060 by HPLC method	61
Fig. 3.6	Calibration plot of DPK-060 by HPLC method	62
Chapter 4: Preformulation study		
Fig. 4.1	Mass spectra of Omiganan	70
Fig. 4.2	Mass spectra of DPK-060	70
Fig. 4.3	Solubility of Omiganan in various excipients	71
Fig. 4.4	Solubility of DPK-060 in various excipients	72
Fig. 4.5	FT-IR spectra of Omiganan	73

Fig. 4.6	FT-IR spectra of Omiganan + lipids mixture (for liposomes)	73
Fig. 4.7	FT-IR spectra of Omiganan + lipids mixture (for NLCs)	74
Fig. 4.8	FT-IR spectra of Omiganan and lipids mixture (for lotion)	74
Fig. 4.9	FT-IR spectra of DPK-060	75
Fig. 4.10	FT-IR spectra of DPK-060 + lipids mixture (NLCs)	75
Fig. 4.11	FT-IR spectra of DPK-060 and lipids mixture (for lotion)	76
Chapter 5A) Formulation Development: Omiganan Nano-lipid Constructs		
Fig. 5A.1	Ishikawa diagram showing probable variables that may influence CQA	85
Fig. 5A.2	Actual v/s Predicted plot for % Drug entrapment	88
Fig. 5A.3	Contour plot (2D) showing the combined effect of lipid concentration and homogenization cycles on % drug entrapment	90
Fig. 5A.4	Contour plot (2D) showing the combined effect of lipid concentration and Smix concentration on % drug entrapment	91
Fig. 5A.5	Contour plot (2D) showing the combined effect of Smix concentration and Homogenization cycles on % drug entrapment	91
Fig. 5A.6	Response surface (3D) showing the combined effect of lipid concentration and Homogenization cycles on % drug entrapment	92
Fig. 5A.7	Response surface (3D) showing the combined effect of lipid concentration and Smix concentration on % drug entrapment	92
Fig. 5A.8	Response surface (3D) showing the combined effect of Smix concentration and Homogenization cycles on % drug entrapment	93
Fig. 5A.9	Actual v/s Predicted plot for Particle size	95
Fig. 5A.10	Contour plot (2D) showing the combined effect of lipid concentration and Homogenization cycles on Particle size	97

Fig. 5A.11	Contour plot (2D) showing the combined effect of lipid concentration and Smix concentration on Particle size	97
Fig. 5A.12	Contour plot (2D) showing the combined effect of Smix concentration and Homogenization cycles on Particle size	98
Fig. 5A.13	Response surface (3D) showing the combined effect of lipid concentration and Homogenization cycles on Particle size	98
Fig. 5A.14	Response surface (3D) showing the combined effect of lipid concentration and Smix concentration on Particle size	99
Fig. 5A.15	Response surface (3D) showing the combined effect of Smix concentration and Homogenization cycles on Particle size	99
Fig. 5A.16	Desirability plot	100
Fig. 5A.17	Overlay plot	102
Fig. 5A.18	Zeta potential of the developed Omiganan nano-lipid constructs	103
Fig. 5A.19	SEM image of the developed Omiganan loaded nano-lipid	104
Fig. 5A.20	Particle size of the optimized Omiganan nano-lipid constructs	104
Chapter 5B) Formulation Development: Omiganan Liposomes		
Fig. 5B.1	Ishikawa diagram showing probable variables that may influence CQA	116
Fig. 5B.2	Actual v/s Predicted plot for % Drug entrapment	120
Fig. 5B.3	Contour plot (2D) showing the combined effect of lipid concentration and sonication amplitude on % drug entrapment	122
Fig. 5B.4	Contour plot (2D) showing the combined effect of lipid concentration and sonication time on % drug entrapment	122
Fig. 5B.5	Contour plot (2D) showing the combined effect of sonication time and sonication amplitude on % drug entrapment	123

Fig. 5B.6	Response surface (3D) showing the combined effect of lipid concentration and sonication amplitude on % drug entrapment	123
Fig. 5B.7	Response surface (3D) showing the combined effect of lipid concentration and sonication time on % drug entrapment	124
Fig. 5B.8	Response surface (3D) showing the combined effect of sonication time and sonication amplitude on % drug entrapment	124
Fig. 5B.9	Actual v/s Predicted plot for vesicle size	126
Fig. 5B.10	Contour plot (2D) showing the combined effect of lipid concentration and sonication amplitude on vesicle size	128
Fig. 5B.11	Contour plot (2D) showing the combined effect of lipid concentration and sonication time on vesicle size	129
Fig. 5B.12	Contour plot (2D) showing the combined effect of sonication time and sonication amplitude on vesicle size	129
Fig. 5B.13	Response surface (3D) showing the combined effect of lipid concentration and sonication amplitude on vesicle size	130
Fig. 5B.14	Response surface (3D) showing the combined effect of lipid concentration and sonication time on vesicle size	130
Fig. 5B.15	Response surface (3D) showing the combined effect of sonication time and sonication amplitude on vesicle size	131
Fig. 5B.16	Desirability plot	132
Fig. 5B.17	Overlay plot	134
Fig. 5B.18	Zeta potential of the developed Omiganan liposomes	135
Fig. 5B.19	Cryo-TEM images of the developed Omiganan loaded liposomes	136
Fig. 5B.20	Vesicle size of the optimized Omiganan liposomes	136
Chapter 6A) Formulation Development: DPK-060 Nano-lipid Constructs		
Fig. 6A.1	Ishikawa diagram showing probable variables that may influence CQA	153

Fig. 6A.2	Actual v/s Predicted plot for % Drug entrapment	156
Fig. 6A.3	Contour plot (2D) showing the combined effect of lipid concentration and homogenization cycles on % drug entrapment	158
Fig. 6A.4	Contour plot (2D) showing the combined effect of lipid concentration and Surfactant concentration on % drug entrapment	159
Fig. 6A.5	Contour plot (2D) showing the combined effect of Surfactant concentration and Homogenization cycles on % drug entrapment	159
Fig. 6A.6	Response surface (3D) showing the combined effect of lipid concentration and Homogenization cycles on % drug entrapment	160
Fig. 6A.7	Response surface (3D) showing the combined effect of lipid concentration and Surfactant concentration on % drug entrapment	160
Fig. 6A.8	Response surface (3D) showing the combined effect of Surfactant concentration and Homogenization cycles on % drug entrapment	161
Fig. 6A.9	Actual v/s Predicted plot for Particle size	163
Fig. 6A.10	Contour plot (2D) showing the combined effect of lipid concentration and Homogenization cycles on Particle size	165
Fig. 6A.11	Contour plot (2D) showing the combined effect of lipid concentration and Surfactant concentration on Particle size	165
Fig. 6A.12	Contour plot (2D) showing the combined effect of Surfactant concentration and Homogenization cycles on Particle size	166
Fig. 6A.13	Response surface (3D) showing the combined effect of lipid concentration and Homogenization cycles on Particle size	166
Fig. 6A.14	Response surface (3D) showing the combined effect of lipid concentration and Surfactant concentration on Particle	167

	size	
Fig. 6A.15	Response surface (3D) showing the combined effect of Surfactant concentration and Homogenization cycles on Particle size	167
Fig. 6A.16	Desirability plot	169
Fig. 6A.17	Overlay plot	171
Fig. 6A.18	Zeta potential of the developed DPK-060 nano-lipid constructs	172
Fig. 6A.19	SEM image of the developed DPK-060 loaded nano-lipid constructs	173
Fig. 6A.20	Particle size of the optimized DPK-060 nano-lipid constructs	173
Chapter 7 *In-vitro* and *ex-vivo* studies		
Fig. 7.1	*In-vitro* drug release profiles of Omiganan loaded formulations	191
Fig. 7.2	*In-vitro* drug release profiles of DPK 060 loaded formulations	191
Fig. 7.3	*In-vitro* cell viability data for Omiganan formulations in 3T3-fibroblast cells	195
Fig. 7.4	*In vitro* cell viability data for DPK-060 formulations in 3T3-fibroblast cells	195
Fig. 7.5	*In vitro* cell uptake of Omiganan formulations in 3T3-fibroblast cells	197
Fig. 7.6	*In vitro* cell uptake of DPK 060 formulations in 3T3-fibroblast cells	198
Fig. 7.7	Results of hemocompatibility study of Omiganan & DPK 060 formulations	200
Fig. 7.8	Protease degradation assay of Omiganan loaded formulations	202
Fig. 7.9	Protease degradation assay of DPK 060 loaded formulations	202

Fig. 7.10	Fluorescence microscopic images of mice skin sections after 6 h of treatment with Omiganan formulations	205
Fig. 7.11	Fluorescence microscopic images of mice skin sections after 6 h of treatment with DPK 060 formulations	206
Chapter 8 *In-vivo* studies		
Fig. 8.1	Imiquimod induced psoriatic animal model development on the back skin and right ear	216
Fig. 8.2	Visual analysis of improvement in psoriatic lesions after treatment; A) Normal control, B) Model control (Only Imiquimod), C) Standard control (Betamethasone Dipropionate gel, Betagel), D) Free Omiganan gel, E) Omiganan lotion, F) Omiganan liposomal gel, G) Omiganan NLC gel	217
Fig. 8.3 A	Erythema score	218
Fig. 8.3 B	Scaling score	218
Fig. 8.3 C	Skin thickening score	219
Fig. 8.3 D	Total PASI score	219
Fig. 8.4	% Change in spleen weight	220
Fig. 8.5	Visual analysis and comparison of spleen size after treatment; A) Normal control, B-C) Standard control (Betamethasone Dipropionate gel, Betagel), D) Free Omiganan gel, E) Omiganan lotion, F) Omiganan liposomal gel, G) Omiganan NLC gel, H-I) Model control (Only Imiquimod)	221
Fig. 8.6	% Change in body weight	221
Fig. 8.7	Histopathological images of mice skin for different animal groups; A) Normal control, B) Model control (Only Imiquimod); Blue arrow indicates hyperkeratosis, black arrow indicates acanthosis, orange arrow indicates the presence of inflammatory cells, C) Free Omiganan gel, D) Omiganan lotion, E) Standard control (Betamethasone Dipropionate gel, Betagel), F) Omiganan liposomal gel, G)	222

	Omiganan NLC gel	
Fig. 8.8	IL-6 and TNF- α levels for different animal groups after treatment	223
Fig. 8.9	Ovalbumin induced eczema animal model development	224
Fig. 8.10	Visual analysis of improvement in eczematic lesions after treatment; A) Normal control, B) Model control (Only Ovalbumin), C) Standard control (Betamethasone Dipropionate gel, Betagel), D) Free Omiganan gel, E) Omiganan lotion, F) Omiganan liposomal gel, G) Omiganan NLC gel, H) Free DPK-060 gel, I) DPK-060 lotion, J) DPK-060 NLC gel	224
Fig. 8.11	Histopathological images of mice skin for different animal groups; A) Normal control, B) Model control (Only Ovalbumin, C) Free Omiganan gel, D) Omiganan lotion, E) Omiganan Liposomal gel, F) Omiganan NLC gel, G) Standard control (Betamethasone Dipropionate gel, Betagel), H) Free DPK-060 gel, I) DPK-060 lotion, J) DPK-060 NLC gel	225
Fig. 8.12	Skin thickness for different animal groups after treatment	226
Fig. 8.13	IL-4 levels for different animal groups after treatment	227
Fig. 8.14	TNF-α levels for different animal groups after treatment	227
Fig. 8.15	IL-6 levels for different animal groups after treatment	228